Abstract: The present disclosure relates to a method and system for generating a user specific content. The method comprises receiving, by a processing unit, a user specific input data, a base content, and an e-commerce data. The method further comprises extracting, by the processing unit, a set of features from the user specific input data. Further, the method comprises altering, by the processing unit, the base content based on the e-commerce data and the set of features. Furthermore, the method comprises generating, by the processing unit, the user specific content based on the altering, wherein the user specific content comprises at least one of a user specific visual media, and a user specific audio-visual media.

Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.

Abstract: The present invention relates to Human Immunodeficiency Virus (HIV) prevention and treatment. In particular, the invention relates to a pharmaceutical composition comprising: cabotegravir, a wetting agent; a stabilizer, and a tonicity adjuster, wherein cabotegravir is present in the form of particles having a mass median diameter (X50) of between (and including) 2.5 ?m and 10 ?m.

Abstract: System and method for generating one or more interactive responses for a computing device, said system comprising at least one processing unit connected to a memory. The method comprises generating one or more prompts to be displayed at the computing device. Thereafter, the method comprises receiving in real time one or more input queries from the at least one computing device. The method further comprises identifying one or more interactive attributes based on the one or more input queries and the one or more prompts. Lastly, one or more responses are generated to the one or more input queries and displayed at the display unit of the at least one computing device.

Abstract: A method and a system for automatically generating one or more real time updates for at least one live event is described. In one example, a processing unit is connected to a storage unit and a display unit, said processing unit fetches a content stream of the at least one live event and identifies at least one moment from the content stream. Based on the identified moment, at least one real time update is generated by the processing unit. The generated real time updated is then displayed on the display unit.

Abstract: The present invention relates to a system and method for providing live information screensaver on a living room device. The method comprises fetching, a live information content for the one or more screensaver, the live information content comprising a set of one or more information pieces, extracting a set of keywords in the live information content, the set of keywords comprising one or more keywords related to the one or more information pieces, generating one or more images related to the one or more information pieces, wherein the one or more images are generated based on the one or more keywords, and the one or more information pieces, stitching the one or more images with the one or more information pieces to generate one or more live information screensavers; and providing the one or more live information screensavers.

Abstract: The present invention relates to Human Immunodeficiency Virus (HIV) prevention and treatment. In particular, the invention relates to a pharmaceutical composition comprising: cabotegravir; a wetting agent; a stabilizer; and a tonicity adjuster; wherein cabotegravir is present in the form of particles having a mass median diameter (X50) of between (and including) 2.5 ?m and 10 ?m.

Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.

Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib (Formula I) as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Abstract: The present invention is concerned with dispersible compositions comprising bedaquiline fumarate as an active ingredient. Such compositions are useful in the treatment of tuberculosis and their inherent dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.

Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.

Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Abstract: An example system includes a service proxy controller and a number of service proxy workers. The service proxy controller is configured for providing routing policies for a telecommunications network core. The telecommunications network core includes network functions communicating using a service-based architecture. Each service proxy worker is configured for routing telecommunications network core messages between a respective subset of the network functions by consuming the routing policies from the service proxy controller and enforcing the routing policies from the service proxy controller. Each service proxy worker is configured for providing network status reports to the service proxy controller based on the telecommunications network core messages.

Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.

Abstract: An example system includes a service proxy controller and a number of service proxy workers. The service proxy controller is configured for providing routing policies for a telecommunications network core. The telecommunications network core includes network functions communicating using a service-based architecture. Each service proxy worker is configured for routing telecommunications network core messages between a respective subset of the network functions by consuming the routing policies from the service proxy controller and enforcing the routing policies from the service proxy controller. Each service proxy worker is configured for providing network status reports to the service proxy controller based on the telecommunications network core messages.

Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Abstract: The present invention is concerned with dispersible compositions comprising bedaquiline fumarate as an active ingredient. Such compositions are useful in the treatment of tuberculosis and their inherent dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.

Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.